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Background. Membranous glomerulonephropathy (MN) is the most prevalent cause of nephrotic syndrome in adult humans.
However, the speciﬁc biomarkers of MN have not been fully elucidated. We examined the alterations in gene expression associated
with the development of MN. Methods. Murine MN was induced by cationic bovine serum albumin (cBSA). After full-blown
MN, cDNA microarray analysis was performed to identify gene expression changes, and highly expressed genes were evaluated
as markers both in mice and human kidney samples. Results. MN mice revealed clinical proteinuria and the characteristic diﬀuse
thickeningoftheglomerularbasementmembrane.Therewere175geneswithsigniﬁcantlydiﬀerentexpressionsintheMNkidneys
compared with the normal kidneys. Four genes, metallothionein-1 (Mt1), cathepsin D (CtsD), lymphocyte 6 antigen complex
(Ly6), and laminin receptor-1 (Lamr1), were chosen and quantiﬁed. Mt1 was detected mainly in tubules, Lamr1 was highly
expressed in glomeruli, and CtsD was detected both in tubules and glomeruli. The high expressions of Lamr1 and CtsD were
also conﬁrmed in human kidney biopsies. Conclusion. The murine MN model resembled the clinical and pathological features of
human MN and may provide a tool for investigating MN. Applying cDNA microarray analysis may help to identify biomarkers for
human MN.
1.Introduction
Membranous glomerulonephropathy (MN), characterized
by the presence of diﬀuse thickening of the GBM and subep-
ithelial in situ immune-complex disposition, is the most
common cause of idiopathic nephrotic syndrome in adults
[1]. The clinical course in the majority of patients is slow
and indolent. Spontaneous remissions of proteinuria occur
in approximately one quarter of patients; approximately half
will have stable renal function with or without continued
proteinuria and approximately 30%–40% of patients with
MN develop progressive renal impairment, which results in
end-stage renal failure after 10–15 years [2–4]. Eﬀector cells,
immunoglobulins, inﬂammatory cytokines, complements,
and oxidative stress all participate in the pathogenesis of
MN, although the deﬁnite pathomechanism of MN has
not yet been fully elucidated [5–8]. Persistence of marked
proteinuria, impaired estimated glomerular ﬁltration rate at
the time of discovery, increased urinary excretion rates for
immunoglobulin G, α1-microglobulin, β-2 microglobulin,
or complement proteins, increased interstitial ﬁbrosis,
and/or advanced stages of glomerular structural abnormal-
ities are among the risk factors for a higher propensity of
progression [9, 10]. However, no deﬁnite biomarkers or
prognostic factors have been clearly documented.
Heymann nephritis (HN), a rat model of autoimmune-
mediated glomerulonephritis, is induced by immunization
with rat renal tubular antigen Fx1A or transfusion with anti-
Fx1A Igs [11]. Alternatively, murine models are induced by
repeated doses of cationic bovine serum albumin (cBSA),
which has a similar clinical course and histopathology to
human MN [12, 13]. Due to a limited source of human2 Journal of Biomedicine and Biotechnology
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Figure 1: Clinical manifestations in mice with MN. The biochemical ﬁndings in MN mice revealed normal renal function (a),
hypoalbuminemia (b), hypercholesterolemia (c), and overt proteinuria (d). ∗P<. 05.
tissue being available and the low cost and advantages of
using transgenic mice, this murine MN model may be
suitable for sample experimental applications to investigate
MN. Improved understanding of MN may create new
opportunities for therapeutic intervention which may
beneﬁt patients with MN in the future. Microarray high
throughput techniques have become increasingly important
in basic and applied biomedical researchdue to the eﬃciency
of analyzing large scale gene expressions simultaneously
to investigate the complex molecular basis of pathological
processes on a genomic scale [14–16].
In this study, we used cDNA microarrays to analyze
global gene expressions of cortical renal tissue in this
cBSA-induced MN model. The upregulated genes and their
relevance to the evolution of MN were examined further by
immunohistochemical staining of kidneys from the rats and
humans.
2.MaterialsandMethods
2.1. Experimental Animals. This study was performed in
accordance with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
of Health and was approved by the Animal Care and
Ethics Committee of the National Defense Medical Center
(Taipei, Taiwan). BALB/c mice (4–6 weeks old, about 20g
body weight) were purchased from the National Laboratory
Animal Center (Taipei, Taiwan). The mice were kept in the
Laboratory Animal Center of the National Defense Medical
Center under speciﬁc-pathogen-free conditions.
2.2. MN Animal Model: Induction Method. Six-week-old
BALB/C mice were divided into an experimental group
(group A) and a control group (group B). Both groups A and
B were immunized with 1mg of C-BSA and Freund’s com-
plete adjuvant. Two weeks later, group A was injected intra-
venously with 3mg/kg of c-BSA 3 times weekly every other
day for 4 weeks, and group B received saline with the same
schedule. Preparation of cationic-bovine serum albumin (C-
BSA) was performed as previously described [12, 13].
2.3. Clinical and Pathological Evaluation. Blood and urine
sample are obtained from the mice then microfuged andJournal of Biomedicine and Biotechnology 3
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Figure 2:RenalhistopathologyinmicewithMN.Histopathologyrevealedﬁndingscharacteristicofdiﬀusebasementmembranethickening,
as observed in the (a) hematoxylin and eosin staining, (b) positive granular immunoﬂuorescent staining for IgG, (c) positive granular
immunoﬂuorescent staining for C3, and (d) subepithelial deposition (asterisk). NC: normal control; MN: membranous nephropathy; G:
glomerular basement membrane; L: lumen of capillary; U: urinary space.
stored at −70◦C until assayed. Serum and urine bio-
chemistries were measured as described previously [17].
Proteinuria was calculated as the ratio of urinary protein
(mg/mL) to urinary creatinine (mg/dL) (Up/Ucr).
Renal tissues were snap frozen or ﬁxed in either Carson-
Millonig’s solution for electron microscopy (EM) or 10%
formalin ﬁxative solution for immunohistochemistry (IHC)
and hematoxylin and eosin staining. Frozen renal specimens
were cut with a cryostat into 4-μm sections for the detection
of immunoﬂuorescence (IF).
For IF, the frozen sections were air-dried, ﬁxed in
acetone for 10 min at room temperature, and incubated
with ﬂuorescein isothiocyanate-conjugated goat antimouse
IgG (Cappel; Organon Teknika, Durham, NC). For IHC,
a microwave heating procedure was used as described
previously [18], followed by incubating with goat anti-
Laminreceptor1(R&D,Minneapolis,MN)andCathepsinD
(Santa Cruz, Santa Cruz, CA) at 4◦C overnight. Horseradish
peroxidase-conjugated protein-G (Pierce, Rockford, IL) was
then applied to the sections for 1h. Reaction products
were visualized using a colour solution consisting of AEC
(DAKO, Carpinteria, CA) for 2-3 min, and the slides were
counterstained lightly with haematoxylin.
2.4. Microarray Analysis. The cDNA microarray containing
15000 diﬀerent mouse cDNA clones (http://lgsun.grc.nia.nih
.gov/cDNA/15k.html) was provided by Biochip R&D Center,
Tri-Service General Hospital, Taipei, Taiwan. Total RNA was
extracted from the renal cortices of the normal control
and MN mice and was then annealed to oligo(dT) and
reverse transcribed in the presence of Cy5- and Cy3-labelled
dUTP, respectively. After concentration, the two cDNA
probes were further processed and applied to the slides
for cDNA microarray analysis as described previously [18].
The slides were scanned with a GenePix 4000A scanner
(Axon Instruments, Union City, CA). Data normalization
and analysis were performed as described previously [18].
The average of median ratios from replicates was calculated
for each spot. Spots representing housekeeping genes were
used to normalize the entire slide so that all slides could
be compared directly. Finally, the ratios were taken as log2
transformation, and the SD of the mean was then calculated4 Journal of Biomedicine and Biotechnology
Figure 3: Dendrogram of microarray results from MN kidneys which revealed 175 genes with signiﬁcantly diﬀerent expressions compared
with normal kidneys.
from these log2 ratios for the determination of expression
outliers.
2.5. RNA Extraction and Real-Time Quantitative PCR. Total
R N Aw a se x t r a c t e df r o mt h er e n a lc o r t i c e sw i t hT R I z o l
reagent (Life Technologies, Gaithersburg, MD, USA). First-
strandcomplementaryDNA(cDNA)wassynthesizedusinga
SuperScript III Reverse Transcriptase kit (Life Technologies)
following the standard protocol. Real-time polymerase chain
reaction(PCR)analyseswereperformedusingaSYBRGreen
Master Mix Kit (Bio-Rad) and an Opticon PCR thermal
cycler (MJ Research, Waltham, MA, USA). The relative
expression of each cytokine mRNA was determined and
normalized to the expression of the internal housekeeping
gene GAPDH. All samples were measured in triplicate three
times. Primer and probe sequences are listed in Table 1.
2.6. Statistical Analyses. All data were expressed as mean ±
SD. Statistical analysis was performed by the t-test for two
groups or by analysis of variance (ANOVA) for multiple
groups with Tukey’s post-hoc test. Correlation analysis was
examined by tests of linear regression. Signiﬁcance was
deﬁned as P<. 05.
3. Results
3.1. Clinical and Pathological Evaluation of the MN Model.
Mice with experimental MN developed normal renal func-
tion (Figure 1(a)) and the characteristic clinical symptoms
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Figure 4: Candidate genes mRNA expression levels. Four candidate
genes RNA were prepared from the kidney cortices of NC and MN
mice, and the levels of mRNA expression were determined by RT-
PCR (n = 3). ∗P<. 05.
of hypoalbuminemia (Figure 1(b)), hypercholesterolemia
(Figure 1(c)), and overt proteinuria (Figure 1(d)). Renal
histopathology revealed typical ﬁndings of diﬀuse basement
thickening over the whole glomerular basement membrane
(GBM) in hematoxylin and eosin staining (Figure 2(a)).
Immunoﬂuorescence of IgG and C3 showed a granularJournal of Biomedicine and Biotechnology 5
Table 1: The 175 genes with signiﬁcantly diﬀerent expressions in the MN kidneys compared with the normal kidneys.
Increased expression
Adamts1: a disintegrin and metalloproteinase with thrombospondin
motif type 1 Ly6a: lymphocyte antigen 6 complex, locus A
Akr1b3: aldo-keto reductase family 1, B3 Ly6e: lymphocyte antigen 6 complex,, locus E
Aldo: aldolase 1, A isoform Lyzs: lysozyme
Anxa2: annexin A2 Macs: myristoylated alanine rich protein
Anxa5: annexin A5 Mglap: matrix gamma-carboxyglutamate (gla) protein
Arbp: acidic ribosomal phosphoprotein Morc3: MORC family CW-type zinc ﬁnger 3
Arpclb: actin-related protein Mpz: myelin protein zero
Axl: AXL receptor tyrosine kinase Mrgpre: MAS-related GPR, member E
Bgn: biglycan Mrp63: mitochondrial ribosomal protein 63
C1ga: complement component C1ga Mrps6: mitochondrial ribosomal protein S6
C1gc: complement component C1gc Mt1: metallothionein 1
C3: complement component 3 Mt2: metallothionein 2
Calbl: calbindin-28K Muc1: mucin 1, cell surface associated
Cap 1: adenylyl cyclase-associated protein 1 Muc1: mucin 1, transmembrane
Capg: capping protein (actin ﬁlament) Nes: nestin
Cd24a: CD24a antigen Nfkbia: nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha
Cd9: CD9 antigen Nid1: nidogen 1
Cldn7: claudin 7 Npnt: nephronectin
Clic1: chloride intracellular channel Pcolce: procollagen C-proteinase enhancer
Clu: clusterin Pctp1: phosphatidylcholine transfer protein
Cmkbr2: chemokine (C-C) receptor 2 Plat: plasminogen activator, tissue
Col 3a1: procollagen, type III, alpha 1 Prdx6: peroxiredoxin 6
Col4a1: procollagen, type IV, alpha 1 Prkab1: protein kinase, AMP-activated, beta 1 noncatalytic
subunit
Col4a2: procollagen, type IV, alpha 2 Ptma: prothymosin alpha
Colla2: procollagen, type I, alpha 2 Rab31: member RAS oncogene family
Collal: procollagen, type I, alpha 1 Raph1: Ras association and pleckstrin homology domains 1
Cox7a3: cytochrome c oxidase, subunit 7a3 Rbm3: RNA binding motif protein 3
Csnkld: casein kinase 1 delta Rbm5: RNA binding motif protein 5
Csrp: cysteine rich protein Rhoc: ras homolog gene family, member C
Cst3: cystatin C Rpia: ribose 5-phosphate isomerase A
Ctsc: cathepsin C Rpl12: ribosomal protein L12
Ctsd: cathepsin D Rpl29: ribosomal protein L29
Dbh: dopamine beta-hydroxylase Rpl3: ribosomal protein L3
Dgcr: DiGeorge syndrome critical region Rpl31: ribosomal protein L31
Dgk1: diacylglycerol kinase 1 Rpl36: ribosomal protein L36
Dok7: docking protein 7 Rpl37a: ribosomal protein L37a
Dppa2: developmental pluripotency associated 2 Rpl41: ribosomal protein L41
Dtx1: deltex homolog 1 (Drosophila) Rpl5: ribosomal protein L5
Eef1a1: eukaryotic translation elongation factor 1 alpha 1 Rpl7: ribosomal protein L7
Eif3d: eukaryotic translation initiation factor 3, subunit D Rplp1: ribosomal protein, large, P1
Elk1: member of ETS oncogene family Rps15: ribosomal protein S15
Eras: ES cell expressed Ras Rps15: ribosomal protein S15
F2r: coagulation factor II (thrombin) Rps16: ribosomal protein S16
F9: coagulation factor IX Rps20: ribosomal protein S20
Fau: Finkel-Biskis-Reilly murine sarcoma Rps3a: ribosomal protein S3a6 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Increased expression
Fcerlg: Fc receptor, IgE high aﬃnity Rps4x: ribosomal protein S4, X-linked
Fkbp5: FK506 binding protein 5 Rps6: ribosomal protein S6
Fn1: ﬁbronectin 1 Rrm2: ribonucleotide reductase M2
Fn14: ﬁbroblast growth factor-inducible 14 Rsbn1: round spermatid basic protein 1
Fstl: follistatin-like protein Rundc3a: RUN domain containing 3A
Ft11: ferritin light chain 1 S100a6: S100 calcium binding protein A
Gnb211: guanine nucleotide binding protein Sam68: Src-associated in mitosis, 68kDa
Gpr56: G protein-coupled receptor 56 Sdc4: syndecan 4
H2-Ebl: histocompatibility 2, class 1E beta Serpinb6: serpin peptidase inhibitor, B6
Hcfc1: host cell factor C1 Serping1: serpin peptidase inhibitor, G1
Hdc-c: histidine decarboxylase Serpinh1: serpin peptidase inhibitor, H1
Hmga1: high mobility group A1 Sh3bgrl3: SH3 domain binding glutamic acid-rich protein
like 3
Hmgb2: high mobility group box 2 Sparc: secreted protein acidic and rich in cysteine
Hmgn2: high mobility group nucleosomal binding domain 2 Spp1: secreted phosphoprotein 1
Hn1: hematological and neurological expressed protein 1 Star: steroidogenic acute regulatory protein
Hnrp1: heterogeneous nuclear ribonucleoprotein A1 Syn1: synapsin 1
Hsp25: heat shock protein, 25 kDa Tbst1: protein-tyrosine sulfotransferase 1
Hsp84-1: heat shock protein, 84 kDa 1 Tgfb1i4: transforming growth factor beta 1 induced
transcript 4
Idb2: inhibitor of DNA binding 2 Tip39: tuftelin-interacting protein 33
Klhl2: kelch-like 2, Mayven (Drosophila) Tmsb10: thymosin, beta 10
Krt2-8: keratin complex 2, basic, gene 8 Tmsb4x: thymosin, beta 4, X chromosome
Lamr1: laminin receptor 1 Tpi: triose phosphate isomerase
Laptm5: lysosomal associated protein multispanning transmembrane 5 Tspan2: tetraspanin 2
Lcn2: lipocalin 2 Tuba2: tubulin, alpha 2
Lcn7: lipocalin 7 Tubb5: tubulin, beta 5
Ldh1: lactate dehydroaenase 1 Ubc: ubiquitin C
Lgals3: lectin, galactoside-binding, soluble, 3 Uchrb: Ubiquitin c-terminal hydrolase
Litaf: LPS-induced TNF-alpha factor Ucp2: uncoupling protein 2
Lrat: lecithin retinol acyltransferase Wisp2: WNT1 inducible signaling pathway protein 2
Lu: Lutheran blood group glycoprotein
Decreased expression
Ak4: adenylate kinase 4 Lrp2: low density lipoprotein receptor-related protein 2
Bhmt2: betaine-homocysteine methyltransferase 2 Mad1l1: mitotic arrest deﬁcient-like 1
Bid: BH3 interacting domain death agonist Map4: microtubule-associated protein 4
Ccnc: cyclin C Med28: mediator complex subunit 28
Cdc2a: cell division cycle 2 homolog A Megf10: multiple EGF-like-domains 10
Degs2: degenerative spermatocyte homolog 2 Narg1: NMDA receptor regulated 1
Emp3: epithelial membrane protein 3 Prlr: prolactin receptor
Ensa: endosulﬁne alpha Rac GAP: Rac GTPase activating protein 1
Epha2: Eph receptor A2 Rhd: Rh blood group, D antigen
Evi5: ecotropic viral integration site 5 Rhov: ras homolog gene family, member V
Fignl1: ﬁdgetin-like 1 Slc15a2: solute carrier family 15, member 2
Hmgcs2: 3-hydroxy-3-methylglutaryl CoA synthase 2 Ttr: Transthyretin
Hsd3b: 3-hydroxysteroid dehydrogenase type 2 Xnp: X-linked nuclear proteinJournal of Biomedicine and Biotechnology 7
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Figure 5: Conﬁrmation of candidate protein expressions based on the microarray results by Western blot of kidney protein extraction. NC:
normalcontrol;MN:membranousnephropathy;Mt-1:metallothionein-1;CtsD:cathepsinD;Lamr-1:lamininreceptor-1;Ly6e:lymphocyte
antigen 6 complex (n = 3). ∗P<. 05.
Table 2: PCR gene sequences in four candidate genes and housekeeping genes.
Name Forward Reverse Product (bp)
Ly6e 5 agtcttcctgcctgtgctgttg3  5 cgccacaccgagattgagattg3  253
Lamr-1 5 ctcttatgtcaacctgcccacc3  5 tgctcctccttctcaatctcctc3  221
CtsD 5 agctgtcctacctgaacgtcac3  5 tgtctttccaccctgcgatacc3  287
Mt-1 5 tcaacgtcctgagtaccttctcc3  5 tgaagacctctgcttcctgtcc3  397
GAPDH 5 tccgccccttctgccgatc3  5 cacggaaggccatgccagtga3  354
Ly6e: lymphocyte antigen 6 complex, Lamr-1: laminin receptor-1 (67kDa), CtsD: cathepsin D, Mt-1: metallothionein-1, GAPDH: housekeeping gene, bp:
base pair.
pattern of deposition along the GBM (Figures 2(b) and
2(c)). Electronic microscopy revealed a granular pattern of
deposition over the subepithelial space but no mesangial
electron dense deposits (Figure 2(d)).
3.2. Gene Expression in the Renal Cortex. To determine
the proﬁle of altered gene expression associated with MN,
cDNA microarray chip analysis was performed on cortical
renal tissue from the NC and MN mice. There were 175
genes with signiﬁcantly diﬀerent expressions in the MN
kidneys compared with the normal kidneys (Table 1). Four
enhanced genes related to injury, inﬂammation, and cell-
matrixinteractionwerechosen:Mt-1,CtsD,Lamr-1,andLy6
(Figure 3). To further conﬁrm the upregulated gene proﬁles
in the cortical tissue, we designed primers and performed
quantitative real-time PCR (Table 2). All four chosen genes
revealed signiﬁcant increases in expression as shown using
the microarray chip (Figure 4). These protein expressions
were also conﬁrmed using Western blot (Figure 5).
3.3. Protein Expression and Localization in Kidney from Mice
and Human. We further wanted to determine whether the
gene-encoded protein expressions in the kidney cortices
from the mice of the control and experimental groups
correlated with gene expression. As the main source of
Ly6e is from immune cells, we chose CtsD, Lamr-1, and
Mt-1 gene-encoded proteins using IHC to identify the
cellular source and the glomerular expression in the renal
tissues. Compared with normal controls, MN mice showed
enhanced expressions of all of these three proteins in
the kidneys, which were similar to those shown by the
microarray chip (Figure 6). The CtsD protein was expressed
mainly in tubulointerstitium with a minority in glomeruli
(Figures 6(a) and 6(b)). The expression of Lamr-1 protein
was mainly in the glomeruli and Mt-1 was restricted to the
tubulointerstitium (Figures 6(c)–6(f)). The major objective
of our study was to test whether gene products identiﬁed
from the experimental MN model induced by cBSA could
be applied to human disease. We therefore chose human
CtsD and Lamr-1 proteins, which are expressed in glomeruli,
and performed IHC to check their expressions. As illustrated
in Figures 7(a)–7(d), the enhanced expression pattern was
similar to that in the murine model.
4. Discussion
The murine model of MN induced by cBSA resembles
the clinical and pathological features of human MN and
m a yp r o v i d eat o o lt oi n v e s t i g a t eM N .I nt h i ss t u d y ,w e
used a cursory approach of global gene expression, cDNA8 Journal of Biomedicine and Biotechnology
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Figure 6: Renal immunohistochemistry of candidate proteins in mice kidneys. Kidneys from mice of the normal control group ((a), (c), and
(e)) and membranous nephropathy group ((b), (d), and (f)) were stained for CtsD ((a) and (b)), Lamr-1 ((c) and (d)), and Mt-1 ((e) and
(f)). All images are at 400× magniﬁcation. CtsD: cathepsin D; Lamr-1: laminin receptor-1; Mt-1: metallothionein-1.
microarray, to analyze diﬀerential gene expression associated
with the development of MN from a murine model. Using
real-time mRNA analysis of kidney tissues, we observed that
CtsD,Lamr-1,Mt-1,andLy6ewerediﬀerentiallyupregulated
in aﬀected kidneys and identiﬁed the expressions of these
proteins in kidneys from mice and humans. These proteins
may be viewed as biomarkers associated with the develop-
ment of MN.
Although there was a lack of an evident mechanism
in our ﬁndings, the identiﬁed genes that might contribute
to the pathogenesis or the pathophysiological potential of
each gene need to be further addressed. Normal GBM
contains type IV collagen, noncollagenous glycoproteins,
and heparan sulphate proteoglycans [19]. Laminin is the
major glycoprotein binding to type IV collagen to form the
backboneofbasementmembranesprovidingtensilestrength
and cell-adhesive properties. Previous studies have shown
that there is an increased production of laminin with the
appearance of abnormal laminin isoforms in MN. This has
been proposed to play a role in the occurrence of proteinuria
by modifying the functional properties of GBM and/or by
modifying podocyte functions [20]. The presence of anti-
LMN Ab has been reported in patients with various diseases
involving basement membrane such as Goodpasture syn-
drome and poststreptococcal glomerulonephritis (GN) [21–
23]. However, to the best of our knowledge, this is the ﬁrstJournal of Biomedicine and Biotechnology 9
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Figure 7: Renal immunohistochemistry of candidate proteins in human kidneys. Kidneys from humans of the normal control group (a
and c) and membranous nephropathy group (b and d) were stained for CtsD (a and b) and Lamr-1 (c and d). All images are at 400x
magniﬁcation. CtsD: cathepsin D; Lamr-1: laminin receptor-1.
study to ﬁnd an enhanced expression of laminin receptor-1
in MN. Laminin receptor-1 is a cell-surface receptor for the
extracellular matrix (ECM) glycoprotein laminin with high
aﬃnity and speciﬁcity. It is well established that the receptor
interacts directly with laminin to play important roles both
in cell adhesion to the basement membrane and in signaling
transduction.Inaddition todirectinteractionswithlaminin,
it also has been proposed to facilitate interactions between
laminin and integrins as well as angiogenesis in vascular
endothelial cells [24]. However, which cell type expresses
Lamr-1,howthemoleculeisattributedtotheprocessofMN,
and its deﬁnite mechanism still require further research.
Cathepsin D, a 52-kDa protein and the major pep-
statin A-sensitive aspartate protease within lysosomes, has
been suggested to be involved in several biological activ-
ities including the regulation of apoptotic pathways, the
activation of proteolytic enzymes involved in the degrada-
tion of extracellular matrix components and stimulatory
eﬀects towards cellular proliferation and angiogenesis [25].
Cathepsin D is also a renin-like enzyme that catalyzes
angiotensinogen breakdown to AngI. In normal kidneys, this
enzyme is preferably expressed in the distal tubular system
and the collecting ducts, and its expression is upregulated
in chronic renal disease [26]. Morphological, biochemical,
and physiological heterogeneity of renal lysosomes has been
conﬁrmed in the kidney cortices of GN patients, such as
Goodpasture disease and poststreptococcal GN [27, 28].
Changes in lysosome populations in rat kidney cortices
induced by passive Heymann nephritis have been observed
[29]. Furthermore, we conﬁrmed the protein expression in
human MN kidneys. Metallothionein is a heat stable, low
molecular weight protein participating in chelating heavy
metals and has a physiological role in the scavenging of free
radicals [30]. Ly6e, which belongs to the Ly6 superfamily, is
a small glycoprotein linked to the glycophosphatidylinositol
(GPI) anchor participating in cell signaling and cell adhesion
processes and is involved in lymphocyte activation [31].
Increased Ly6e gene expression in response to proteinuria,
as well as being correlated to lupus activity and renal lesions,
suggests a potential role of Ly6e in the pathophysiology of
renal disease [32]. However, the deﬁnite mechanism is still
unclear.
Microarray high throughput techniques are a very
eﬃcient method to analyze large-scale gene expressions
simultaneously to investigate the complex molecular basis of
pathologicalprocessesonagenomicscale.Theyhavebecome
increasingly important in basic and applied biomedical
research including several renal diseases [14, 33]. However,
a whole-genome gene expression analysis study of MN using
amurinemodelandthenbeingappliedtohumandiseasehas
not been reported. Cluster analysis of DNA microarrays can
better provide an intuitive understanding of how to analyze10 Journal of Biomedicine and Biotechnology
microarray data, making it easier to interpret the meaning
of the results in a biological framework. The main limitation
of the present study is that it addressed gene expression in
kidney cortex instead of glomeruli, which would have been
more meaningful. Murine models of MN induced by cBSA
not only resemble the clinical and pathological features of
human MN, but also oﬀer the advantages of being cheaper
and easy to manipulate and having potential applications in
gene-knockout or transgenic mouse studies on MN.
The precise nature of the idiopathic MN-initiating
antigen is unclear. A pathogenic antigen, megalin (gp 330),
has been identiﬁed in Heymann nephritis but not in human
or mice glomeruli [34]. Although the cBSA used in our
model is an exogenous rather than an endogenous antigen,
its immunopathological speciﬁcity has been proved during
MN. Similar presentations were conﬁrmed by IHC staining
of the human specimens, also demonstrating the value of
this murine MN model. We did not diﬀerentiate which
component of the renal cortex contributed to the gene
expression revealed by cDNA microarray analysis, but both
glomerular and tubular responses composed the kidney
response in MN. Although there was a lack of an evident
functional assay of the genes in our ﬁndings, there is still the
potential to identify biomarkers for human MN. However,
whether these genes play an important role in the pathogen-
esis or pathophysiologies of glomerular injury needs to be
further addressed. Our strategy of using cDNA microarrays
to simultaneously monitor global gene expressions in renal
tissue from the murine cBSA-induced MN model and then
applying the ﬁndings to human disease seemed to work and
to be practical.
Inconclusion,themurinemodelofMNinducedbycBSA
resembled the clinical and pathological features of human
MN and may provide a tool to investigate MN. Applying
cDNA microarray analysis in this model may help to identify
biomarkers for human MN, which may then broaden our
understanding of the possible mechanisms of MN. This may
provide further insight into the disease and generate new
hypotheses for potential novel therapeutic targets in the
future.
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